
    
      This is a non-randomized, single-centre, observational study assessing the incidence of ARCH
      in cancer survivors. Patients over the age of 60 who had or will receive chemotherapy and/or
      radiation therapy for solid or hematologic malignancies at the Princess Margaret Cancer
      Centre will be considered. Based on the time point of treatment, patients will either fall
      into a post or prior chemotherapy/radiation cohort. Peripheral blood will be taken and will
      be sequenced for ARCH DNA mutations. Patients who have ARCH-related mutations at a VAF of at
      least 0.5% we will repeat the genetic sequencing yearly to assess changes in mutational
      spectrum and VAF over time.
    
  